Vitamin K antagonist use and mortality in dialysis patients | Zendy

Pauline Voskamp | Zendy; Maarten B. Rookmaaker | Zendy; Marianne C. Verhaar | Zendy; Friedo W. Dekker | Zendy; Gürbey Ocak | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Vitamin K antagonist use and mortality in dialysis patients

Author(s) -

Pauline Voskamp,

Maarten B. Rookmaaker,

Marianne C. Verhaar,

Friedo W. Dekker,

Gürbey Ocak

Publication year - 2017

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfx199

Subject(s) - medicine , vitamin k antagonist , hazard ratio , dialysis , stroke (engine) , antagonist , end stage renal disease , confidence interval , gastroenterology , hemodialysis , warfarin , atrial fibrillation , mechanical engineering , receptor , engineering

The risk-benefit ratio of vitamin K antagonists for different CHA2DS2-VASc scores in patients with end-stage renal disease treated with dialysis is unknown. The aim of this study was to investigate the association between vitamin K antagonist use and mortality for different CHA2DS2-VASc scores in a cohort of end-stage renal disease patients receiving dialysis treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research